AM24-SN-06-O: Operationalizing Delivery of Gene Therapy for Sickle Cell Disease (Enduring)

CABP CE Eligible

This session focuses on new FDA-approved gene therapies for sickle cell disease (SCD) and the critical aspects of coordinating care for gene therapy, including an approach to transfusion support and maximizing stem cell collections. With recent advancements in gene therapy offering a cure for SCD, effective coordination among multidisciplinary healthcare teams is essential to ensure optimal patient outcomes. Barriers to offering gene therapy for SCD may include alloimmunization to multiple antigens and an inability to collect sufficient autologous hematopoietic stem cells. The session will delve into the details of patient selection, pre-treatment assessments, treatment protocols, and coordination of complex care. Participants will have the opportunity to engage in discussions, case presentations, and a Q&A session with experts in the field of sickle cell disease, gene therapy and transfusion support. The session aims to share best practices and practical strategies for integrating gene therapy into the care plan for patients with SCD at both adult and pediatric institutions.